The Right to Contraception Act establishes a federal statutory right for individuals to obtain contraceptives and to engage in contraception, and it creates a corresponding right for health care providers to provide contraceptives, contraception-related services, information, and referrals. The bill defines ‘‘contraceptive’’ to cover drugs, devices, and biological products authorized under existing FDA and Public Health Service authorities and frames contraception access as a federally protected interest that states and the federal government may not restrict.
The statute reaches state and local laws through broad preemption and eliminates several common legal defenses: it applies notwithstanding RFRA, authorizes the Attorney General and private parties to sue for injunctions, awards prevailing plaintiffs attorney’s fees, and explicitly abrogates state immunity for actions enforcing or maintaining laws that violate the Act. It preserves FDA authority over product approval and does not itself require health plans to cover contraception benefits.
At a Glance
What It Does
The bill creates a statutory right for individuals to obtain contraceptives and for health care providers to offer contraceptives, contraception, and related information; it bars any law that singles out or impedes contraception or contraception providers. It preserves FDA authority over product approval and exempts benefit-mandate questions from changing existing coverage law.
Who It Affects
People seeking contraception and health care providers who prescribe, dispense, or counsel on contraception; State and local governments that have laws restricting contraception or allowing provider refusal; pharmacies, manufacturers, and clinics engaged in interstate commerce.
Why It Matters
This is a direct federal intervention into state regulation of reproductive services: it substitutes a statutory right, preempts conflicting state rules (including some conscience-based restrictions), and supplies robust enforcement tools that make state-level bans or restrictions vulnerable to federal and private litigation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act makes contraception access a statutory federal right. It defines ‘‘contraception’’ broadly (including fertility-awareness methods and sterilization) and ties ‘‘contraceptive’’ to products authorized under the FDA and Public Health Service Act.
By doing so the bill anchors its protections to regulated products and to recognized health care providers.
Section 5 creates reciprocal rights: individuals may obtain contraceptives and voluntarily engage in contraception free from coercion, and providers may offer contraception, information, and referrals. The section bars laws or requirements that expressly or effectively single out contraception, providers who supply it, or facilities where it is offered, or that otherwise impede access.
To defend a challenged limitation, a government or other party must meet a high ‘‘clear and convincing evidence’’ standard showing the limitation actually advances access and that no less restrictive alternative exists. The Act also states that it should not be read to interfere with FDA actions on approvals, clearances, or authorizations.The bill reaches state and federal law through sweeping preemption language: it supersedes any federal or state law that would prohibit or restrict sale, provision, or use of contraceptives or that would impede aiding another person to obtain them.
It explicitly applies ‘‘notwithstanding’’ the Religious Freedom Restoration Act and says later-enacted federal statutes fall under this Act unless they explicitly exclude it. It narrowly preserves existing federal rules governing required insurance benefits, so the Act does not itself force insurers to add new contraceptive benefits.Enforcement is robust.
The Attorney General may sue states or government officials who implement or enforce violating limitations. The Act also creates a private right of action for ‘‘any individual or entity’’ adversely affected, and explicitly allows providers to sue on behalf of patients and staff.
Courts can issue equitable relief; prevailing plaintiffs recover costs and attorney’s fees, and plaintiffs in nonfrivolous suits are insulated from fee exposure. The statute removes state immunity defenses for officials or states that maintain or enforce violating measures and grants federal courts jurisdiction without any administrative exhaustion requirement.
The Five Things You Need to Know
Section 5 bars any law or requirement that ‘‘expressly, effectively, implicitly, or as-implemented singles out’’ contraception, contraception providers, or facilities that offer contraception.
To justify a restriction, the challenger must prove by clear and convincing evidence that the restriction ‘‘significantly advances access’’ to contraception and that no less restrictive alternative exists — an unusually demanding defensive standard.
The Act declares it applies notwithstanding the Religious Freedom Restoration Act (RFRA), signaling Congress’s intent to limit RFRA-based defenses to contraception-access claims.
Section 6 explicitly preserves existing federal health coverage law: the bill does not require group health plans, individual insurers, or federal health programs to add contraceptive benefits.
Enforcement tools include Attorney General suits, a broad private right of action for individuals and providers, courts’ equitable relief, mandatory attorney’s fees for prevailing plaintiffs, and abrogation of state and official sovereign immunity.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Definitions that set the scope of protection
This section defines key terms: ‘‘contraception’’ (broadly including methods, devices, and sterilization), ‘‘contraceptive’’ (tied to products authorized under specific FDA and PHS statutory provisions), ‘‘health care provider’’ (licensed clinicians and entities), and ‘‘State’’ (including territories and local subdivisions). The choice to anchor ‘‘contraceptive’’ to FDA/PHS authorization narrows the universe of covered products to those in regulated channels while keeping the coverage broad enough to include devices, drugs, and biologicals.
Statutory right to obtain and provide contraception and the defensive standard
Section 5(a) creates reciprocal statutory rights: individuals may obtain contraceptives and voluntarily engage in contraception, and providers may supply contraceptives and related information and referrals. Section 5(b) prohibits limitations that single out contraception, providers, or facilities or that impede access generally. Importantly, Section 5(c) sets a high bar for anyone defending a challenged limitation: they must show by clear and convincing evidence that the limitation ‘‘significantly advances access’’ and that there is no less restrictive alternative — in practice, a steep evidentiary hurdle for laws that restrict access. Section 5(d) preserves FDA authority, so court disputes will likely involve whether a challenged product or practice is covered by the FDA-linked definition.
Broad preemption, RFRA override, and coverage carve-out
Section 6(a) states that the Act supersedes federal and state law to the extent it restricts contraceptives, their sale, provision, use, or aiding others to obtain them. It expressly applies ‘‘notwithstanding’’ RFRA, indicating Congress’s view that RFRA cannot be used to justify contraception restrictions. Subsection (b) makes future federal laws subject to this Act unless they explicitly exclude it, while subsection (c) carves out Federal health plan and program coverage law: the Act does not itself create new benefits under ERISA, Medicare/Medicaid, or ACA preventive-service rules. That carve-out preserves disputes over practical access (cost and coverage) even while removing many legal barriers to provision and sale.
Interpretive rules and consent safeguard
Section 7 directs courts to construe the Act liberally to accomplish the statute’s purposes and clarifies that the Act does not authorize government interference with providers’ ability to provide contraception or permit non-consensual sterilization. It also treats private individuals who are empowered by statute to implement or enforce restrictions as ‘‘government officials’’ for purposes of the Act — a drafting choice that widens the pool of defendable targets in litigation and avoids certain agency-only carve-outs.
Enforcement architecture: AG, private suits, fees, and abrogation of immunity
Section 8 gives the Attorney General a cause of action to enjoin states or government officials who violate Section 5, and it creates a broad private right of action allowing any adversely affected individual or entity — explicitly including providers acting on behalf of patients and staff — to sue. Courts may grant equitable relief (temporary to permanent injunctions) and must award litigation costs and reasonable attorney’s fees to prevailing plaintiffs; plaintiffs in nonfrivolous suits are protected from fee exposure. The section also removes state sovereign immunity defenses (Eleventh Amendment and Tenth Amendment), making it easier to bring actions against states or their officials in federal court without administrative exhaustion.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals seeking contraception (including minors and people traveling across state lines) — they gain a federal statutory right to obtain contraceptives and related information and may sue to enjoin state restrictions that single out or impede access.
- Health care providers and clinics that offer contraception — the Act protects providers’ right to provide contraception, allows them to sue on behalf of patients and staff, and narrows the legal space for state refusal laws.
- Pharmacies, manufacturers, and retailers of FDA-authorized contraceptives — state bans on sale or distribution become vulnerable to preemption claims, reducing legal uncertainty for interstate commerce actors.
- Reproductive health and family-planning programs that rely on federal standards — they get a federal backstop against state-level restrictions that would limit service delivery or supplier relationships.
Who Bears the Cost
- State governments and localities with existing or pending restrictions on contraception — they face litigation risk, injunctions, and the loss of sovereign-immunity defenses when enforcing such laws.
- Public officials and agencies charged with implementing restrictive laws — individuals designated to enforce those rules can be sued as ‘‘government officials,’’ exposing them to injunctions and fee awards.
- Religiously affiliated providers, hospitals, and employers relying on state conscience protections — those entities will face greater exposure to legal challenge when their refusal policies impede access to contraception.
- Federal courts and the Justice Department — the AG’s authority to sue plus a flood of private suits will increase litigation workload and require resource allocation to defend or enforce the statute.
Key Issues
The Core Tension
The central dilemma is balancing a robust, nationwide right to contraception with traditional state authority and conscience protections: the bill aggressively protects individual access and provider supply by preempting state restrictions and curtailing RFRA defenses, but in doing so it forces a trade-off between uniform access and the autonomy of states, local institutions, and religious actors — a conflict that courts will have to resolve without an obvious legal or policy ‘‘perfect’’ answer.
The Act resolves one problem — legal barriers erected by state laws and some federal defenses to contraception access — by substituting a strong federal statutory right and powerful enforcement tools. That solution creates several implementation and constitutional flashpoints.
First, the bill’s ‘‘applies notwithstanding RFRA’’ language and abrogation of state immunity will provoke immediate constitutional litigation over separation of powers and the scope of Congress’s authority, particularly where states argue that sovereign immunity and federalism limit federal intervention. Second, the statute ties the definition of ‘‘contraceptive’’ to FDA/PHS-authorized products; disputes over whether a specific product or practice falls within that regulatory frame (for example, off-label uses or novel fertility-awareness tools) will become threshold issues in litigation.
A separate practical tension is between the Act’s strong legal right and its explicit non-interference with federal coverage rules. The Act stops states from banning sale or provision, but it does not mandate insurance coverage or remove cost barriers, so access in practice may continue to vary by payer and locality even where provision is legally protected.
Finally, the unusually high ‘‘clear and convincing evidence’’ standard required to justify a restriction flips the usual burden calculus: defendants must show that a restriction actually advances access — a counterintuitive requirement that courts will need to interpret. Implementation will hinge on how courts read phrases like ‘‘impedes access’’ and ‘‘singles out,’’ and whether narrowly tailored state regulations (for licensing, safety, or supply chain concerns) survive under the Act’s strict defensive test.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.